Biotech Values

[genisi]

MYGN has some proprietary database of mutations so interpretation of results may not be as good that from MYGN, at least early on

Right you are. MYGN does have the advantage of a more detailed BRCA variant database accumulated (and deliberately not shared in all) for long time. This gives them higher accuracy when interpreting test results. However, in most cases variant classification does not require MYGN's database. In fact, in most cases, a very cheap small panel test for the more common mutations (such as for the Ashkenazi Jewish descent), makes BRACAnalysis or full Sanger sequencing of BRCA1/2 unnecessary. In case the cheap panel comes back negative, one can order the full Sanger sequencing and that would still cost half the BRACAnalysis price. So, MYGN's database is only needed for extremely rare variants that the genetic adviser suspects have clinical meaning and are not in the public domain database. I think it won't be long before MYGN's share of this market in the US will shrink.